What’s the true story on RO . Is this another sy
Post# of 148114
(Total Views: 450)
Posted On: 03/10/2021 11:16:52 AM
What’s the true story on RO . Is this another syringe story ? All opinions welcome . Cmon let’s hear it from the well read group . Did NP just throw BPatterson under the bus because of the fued. It’s getting real old real fast trying to get straight answers from this company . Lots of drama . Cmon just spit it out . This thing about NP blaming investors for not understanding or having patience is PMO .
Posted By: gestalt2
Re: reallypeople? #82515
https://pubmed.ncbi.nlm.nih.gov/18333870/
"Conclusions: Maraviroc receptor occupancy close to the maximum is required to induce a significant decrease in viral load, indicating that in vivo CCR5 receptor occupancy by maraviroc is not a direct measure of drug inhibitory activity. Considering the imprecision of the measurement in the upper flat part of the maraviroc concentration vs. percent CCR5 occupancy curve, it can reasonably be concluded that routine monitoring of receptor occupancy as a biomarker for maraviroc efficacy will not be helpful. Based on this analysis, it was decided not to use receptor occupancy as a biomarker of viral load inhibition during the development of CCR5 antagonist compounds."
This was not hard to find, which makes me think there must be some other reason for the leronlimab occupancy data to be quetioned?
Posted By: gestalt2
Re: reallypeople? #82515
https://pubmed.ncbi.nlm.nih.gov/18333870/
"Conclusions: Maraviroc receptor occupancy close to the maximum is required to induce a significant decrease in viral load, indicating that in vivo CCR5 receptor occupancy by maraviroc is not a direct measure of drug inhibitory activity. Considering the imprecision of the measurement in the upper flat part of the maraviroc concentration vs. percent CCR5 occupancy curve, it can reasonably be concluded that routine monitoring of receptor occupancy as a biomarker for maraviroc efficacy will not be helpful. Based on this analysis, it was decided not to use receptor occupancy as a biomarker of viral load inhibition during the development of CCR5 antagonist compounds."
This was not hard to find, which makes me think there must be some other reason for the leronlimab occupancy data to be quetioned?
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼